xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

300

International consensus statement on rhinosinusitis

INCS pts have higher rates of resolution, shorter time to

success (6 vs 9 days); and trend toward fewer recurrences

Delay in clinical improvement with topical antibiotic and

steroid at 48 hours, but similar results at 10 days

INCS improved congestion, facial pain, and headache significantly No difference in purulent

rhinorrhea, PND or cough

Inanli 417 2002 3 Cohort (n = 60) Amoxicillin/clavulanate 875 mg BIDplus: No topical therapy (n = 12) Fluticasone 100 μ gdaily (n = 14) NasalMCC No difference in basal MCC with INCS

improved symptoms with no

significant change in CT score

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions

High and low dose INCS

Symptoms improved at 10-56days Time to success

Number of ARS recurrences Symptom

VAS subjective symptom

improvement

improvement

Change from baseline symptoms and CT normalization

Dolor 421 2001 2 RCT(n = 95) Fluticasone propionate 200 μ g daily (n = 47) Placebo (n = 48)

Amoxicillin (90 mg/kg) (n = 20)

Meltzer 435 2000 2 RCT(n = 407) Mometasone furoate 400 μ gBID

Nayak 419 2002 2 RCT(n = 967) Amoxicillin/clavulanate 875 mg BIDplus: Mometasone 400 μ gBID (n = 324) Mometasone 200 μ gBID (n = 318) Placebo (n = 325)

El-Hennawi 436 2015 3 RCT(n = 40) Ofloxacin 0.26% +

0.05% oxymetazoline TID (n = 9) 3%NaCl (n = 12) 0.9% NaCl (n = 13)

Amoxicillin/clavulanate 875 mgBID(n = 207)

+ Amoxicillin/clavulanate 875 mgBID (n = 200) Placebo spray +

dexamethasone 0.053% nasal drops (n = 20)

TABLE VII-11 (Continued)